Dr. Lal Path Labs Ltd. Stock Price Today (NSE: LALPATHLAB)
Fundamental Score
Dr. Lal Path Labs Ltd. Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Dr. Lal Path Labs Ltd. share price today is ₹1913.70, up +0.65% on NSE/BSE as of 25 August 2026. Dr. Lal Path Labs Ltd. (LALPATHLAB) is a Large-cap company in the Healthcare Service Provider sector with a market capitalisation of ₹28.91K (Cr). The 52-week high for LALPATHLAB share price is ₹3540.00 and the 52-week low is ₹1272.60. At a P/E ratio of 53.35x, LALPATHLAB is currently trading above its industry average P/E of 42.23x. The company has a Return on Equity (ROE) of 21.57% and a debt-to-equity ratio of 0.00.
Dr. Lal Path Labs Ltd. Share Price Chart — NSE/BSE Historical Performance
Dr. Lal Path Labs Ltd. share price chart: 12.29% return over the past month. 52-week high ₹3540.00, 52-week low ₹1272.60.
Dr. Lal Path Labs Ltd. — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹1893.80 | ₹1929.80 | ₹1875.10 | ₹1913.70 | 1.95L (Cr) | |
| ₹1885.00 | ₹1912.00 | ₹1874.00 | ₹1901.40 | 2.12L (Cr) | |
| ₹1968.40 | ₹1968.40 | ₹1907.90 | ₹1916.30 | 2.30L (Cr) | |
| ₹1957.20 | ₹1977.00 | ₹1937.30 | ₹1968.40 | 2.05L (Cr) | |
| ₹1954.80 | ₹1988.90 | ₹1940.00 | ₹1953.30 | 3.51L (Cr) | |
| ₹1954.20 | ₹1955.10 | ₹1917.10 | ₹1949.90 | 1.99L (Cr) | |
| ₹1939.70 | ₹1973.50 | ₹1934.00 | ₹1954.00 | 2.91L (Cr) | |
| ₹1928.00 | ₹1947.90 | ₹1907.10 | ₹1931.60 | 1.58L (Cr) | |
| ₹1882.00 | ₹1949.00 | ₹1880.00 | ₹1928.00 | 4.27L (Cr) | |
| ₹1899.90 | ₹1915.00 | ₹1863.00 | ₹1887.10 | 3.18L (Cr) |
Dr. Lal Path Labs Ltd. — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹1920.00 | ₹1988.90 | ₹1863.00 | ₹1913.70 | -0.33% | |
| ₹1640.80 | ₹1919.80 | ₹1610.10 | ₹1905.20 | +16.11% | |
| ₹1611.20 | ₹1798.66 | ₹1496.49 | ₹1646.20 | +2.17% | |
| ₹1390.40 | ₹1719.90 | ₹1390.00 | ₹1607.40 | +15.61% | |
| ₹1316.20 | ₹1471.50 | ₹1285.00 | ₹1367.20 | +3.87% | |
| ₹1361.00 | ₹1428.30 | ₹1272.60 | ₹1312.10 | -3.59% | |
| ₹1424.60 | ₹1474.00 | ₹1363.30 | ₹1399.90 | -1.73% | |
| ₹1483.30 | ₹1520.00 | ₹1345.20 | ₹1409.50 | -4.98% | |
| ₹3055.00 | ₹3069.20 | ₹1348.00 | ₹1482.60 | -51.47% | |
| ₹3154.90 | ₹3309.20 | ₹3024.40 | ₹3051.80 | -3.27% | |
| ₹3105.00 | ₹3235.00 | ₹3002.90 | ₹3135.50 | +0.98% | |
| ₹3308.80 | ₹3540.00 | ₹3102.00 | ₹3118.10 | -5.76% |
AI Research Briefing
Powered by Gemini · 2026-04-09
Overvalued and facing margin pressure, Dr. Lal PathLabs is a risky bet despite expansion plans.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Dr. Lal PathLabs is set to announce FY26 results on April 30, 2026, and the trading window is closed until May 2. In March 2026, the company issued a notice regarding the transfer of unclaimed equity shares to the IEPF. The board approved the acquisition of immovable property in New Delhi for in September 2025.
CORE STORY (THE REAL GAME)
Dr. Lal PathLabs is a diagnostics chain navigating the shift towards integrated wellness and technology-driven healthcare in India. The market is watching to see if they can maintain growth and margins amidst increasing competition and the need for continuous investment in technology and infrastructure.
- FY26 results due on April 30, 2026
- Seeking acquisitions in South India
- Completed Suburban Diagnostics liquidation
- Successful acquisition in South India
- Better-than-expected FY26 results
- Significant technological breakthrough
- High P/E ratio compared to industry average
- Intense competition in the diagnostics sector
- Integration risks with future acquisitions
FII decreased holdings from 21.86% to 20.29% in Dec 2025. DII have increased holdings from 18.49% to 19.20% in Dec 2025.
Healthcare in India is moving towards digital integration and preventive care.
Acquisition of immovable property in New Delhi for ₹74.51 crore approved in September 2025.
Yes - Free Cash Flow 5Y: ₹1717.61 Cr.
Focus on acquisitions in South India and technology integration. Success hinges on execution and margin management.
Primary Thesis Risk
Inability to maintain margins amidst competition and tech investments.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Dr. Lal Path Labs Ltd. Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Dr. Lal Path Labs Ltd. Fundamental Analysis & Valuation Benchmarking
Educational evaluation of LALPATHLAB across key market metrics for learning purposes.
Positive Indicators
12 factors identified
Strong Return on Equity (21.57%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (27.62%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (28.56%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (28.02%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (19.10%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (30.35x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 3.48)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Strong Cash Generation (₹1843.67 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (53.21%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Strong Institutional Confidence (FII+DII: 38.55%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
Premium Valuation Risk (P/E: 53.35x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
High Price-to-Book Ratio (11.53x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Weak Earnings Growth (-3.06% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Dr. Lal Path Labs Ltd. vs Healthcare Service Provider Peers
Peer Comparison - Healthcare Service Provider
Compare Dr. Lal Path Labs Ltd. with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Dr. Lal Path Labs Ltd.Dr. Lal Path La...Selected✓ LALPATHLAB • 539524 | 57.7/100 | ₹1913.70₹1914 | ₹28908.91₹28908.91 | 53.35Average 53.3 Average | 21.57%Excellent 21.57% Excellent | 27.62%Excellent 27.62% Excellent | 0.00Excellent 0.0 Excellent | 11.60%Good 11.60% Good | 11.81%Good 11.81% Good | 0.81% |
Vijaya Diagnostic Centre LimitedVijaya Diagnost... VIJAYA • 543350 | 67.8/100 | ₹1497.30₹1497 | ₹14307.85₹14307.85 | 76.31Average 76.3 Average | 19.74%Good 19.74% Good | 21.32%Excellent 21.32% Excellent | 0.00Excellent 0.0 Excellent | — — | — — | 0.14% |
Metropolis Healthcare LimitedMetropolis Heal... METROPOLIS • 542650 | 57.9/100 | ₹551.95₹552 | ₹11858.49₹11858.49 | 58.81Average 58.8 Average | 13.36%Average 13.36% Average | 16.80%Good 16.80% Good | 0.01Excellent 0.0 Excellent | 0.74%Average 0.74% Average | 10.52%Good 10.52% Good | 0.35% |
Thyrocare Technologies LimitedThyrocare Techn... THYROCARE • 539871 | 46.7/100 | ₹608.25₹608 | ₹8420.27₹8420.27 | 47.76Average 47.8 Average | 28.80%Excellent 28.80% Excellent | 35.47%Excellent 35.47% Excellent | 0.00Excellent 0.0 Excellent | — — | 10.88%Good 10.88% Good | 1.76% |
Krsnaa Diagnostics LimitedKrsnaa Diagnost... KRSNAA • 543328 | 31.9/100 | ₹540.20₹540 | ₹1777.47₹1777.47 | 21.62Average 21.6 Average | 10.89%Average 10.89% Average | 13.05%Average 13.05% Average | 0.55Good 0.5 Good | — — | — — | 0.50% |
Suraksha Diagnostic LimitedSuraksha Diagno... SURAKSHA • 544293 | 56.2/100 | ₹318.30₹318 | ₹1359.30₹1359.30 | 37.97Average 38.0 Average | 14.11%Average 14.11% Average | 16.82%Good 16.82% Good | 0.01Excellent 0.0 Excellent | — — | — — | 0.00% |
One Global Service Provider LimitedOne Global Serv... ONEGLOBAL • 514330 | 82.2/100 | ₹537.05₹537 | ₹1178.25₹1178.25 | — — | — — | — — | — — | — — | — — | 0.00% |
3B Blackbio Dx Limited3B Blackbio Dx ... 3BBLACKBIO • 532067 | 60.3/100 | ₹1148.40₹1148 | ₹1079.13₹1079.13 | — — | — — | — — | — — | — — | — — | 0.31% |
Sastasundar Ventures LtdSastasundar Ven... SASTASUNDR • 533259 | 39/100 | ₹301.45₹301 | ₹1035.54₹1035.54 | 539.34Average 539.3 Average | 0.29%Poor 0.29% Poor | -0.05%Poor -0.05% Poor | 0.04Excellent 0.0 Excellent | 16.91%Excellent 16.91% Excellent | 19.09%Excellent 19.09% Excellent | 0.00% |
49.4/100 | ₹240.00₹240 | ₹600.78₹600.78 | 20.55Average 20.6 Average | 19.92%Good 19.92% Good | 23.27%Excellent 23.27% Excellent | 0.31Excellent 0.3 Excellent | — — | — — | 0.00% | |
Aspira Pathlab & Diagnostics LimitedAspira Pathlab ... ASPIRA • 540788 | 11.9/100 | ₹93.70₹94 | ₹88.52₹88.52 | 1770.34Average 1770.3 Average | 0.51%Poor 0.51% Poor | 2.84%Poor 2.84% Poor | 0.27Excellent 0.3 Excellent | -48.50%Poor -48.50% Poor | 10.43%Good 10.43% Good | 0.00% |
Top Healthcare Service Provider Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Vijaya Diagnostic Centre Limited share price14307.85 Cr
- Metropolis Healthcare Limited share price11858.49 Cr
- Thyrocare Technologies Limited share price8420.27 Cr
- Krsnaa Diagnostics Limited share price1777.47 Cr
- Suraksha Diagnostic Limited share price1359.30 Cr
Dr. Lal Path Labs Ltd. PE Ratio History
Historical price-to-earnings ratio for LALPATHLAB — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹58.40 | ₹1482.60 | 25.4x |
| FY 2024 | ₹42.98 | ₹3000.40 | 69.8x |
| FY 2023 | ₹28.74 | ₹2577.70 | 89.7x |
| FY 2022 | ₹41.57 | ₹2260.45 | 54.4x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Dr. Lal Path Labs Ltd. Dividend History
Annual cash dividends paid by LALPATHLAB — dividend yield 0.81%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹207.30 Cr |
| FY 2024 | ₹201.17 Cr |
| FY 2023 | ₹103.01 Cr |
| FY 2022 | ₹116.70 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Dr. Lal Path Labs Ltd. Quarterly Performance
Latest quarterly metrics for LALPATHLAB — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
19.10%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
28.02%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
11.81%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
11.60%
Compounded annual net profit growth over 5 years
Dr. Lal Path Labs Ltd. Technical Indicators
SMA 50, SMA 200, RSI and volume signals for LALPATHLAB — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Dr. Lal Path Labs Ltd. Financial Statements
Annual income statement, balance sheet and cash flow for Dr. Lal Path Labs Ltd. (LALPATHLAB) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Dr. Lal Path Labs Ltd.
About LALPATHLAB (Dr. Lal Path Labs Ltd.)
Dr Lal PathLabs Ltd is a prominent healthcare service provider specializing in diagnostic and related healthcare tests. With a long-standing reputation built over decades, the comp...any serves as a crucial bridge between medical professionals and patients, offering a comprehensive suite of diagnostic services. Their network encompasses a broad spectrum of tests, from routine blood work to sophisticated genetic and molecular analyses, all performed within state-of-the-art laboratory environments. Leveraging advanced technology and stringent quality control measures, Dr Lal PathLabs provides accurate and timely results that are essential for informed clinical decision-making, aiding in the diagnosis, treatment, and monitoring of various health conditions. The company's operational capabilities extend beyond conventional diagnostics, encompassing specialized testing in areas such as infectious diseases, oncology, and reproductive health. These advanced services cater to the increasing demand for personalized medicine and precision diagnostics, empowering clinicians with insights crucial for tailoring treatments to individual patient needs. Dr Lal PathLabs consistently invests in research and development to stay at the forefront of diagnostic innovation, ensuring that their test menu reflects the latest advancements in medical science. Moreover, their commitment to accessibility is reflected in a widespread network of collection centers, making diagnostic services readily available to a diverse population across geographical regions. Beyond their core testing services, Dr Lal PathLabs also contributes to healthcare advancement through training and educational initiatives. They offer programs aimed at enhancing the skills and knowledge of healthcare professionals, particularly in areas related to phlebotomy and laboratory techniques. This commitment to professional development strengthens the broader healthcare ecosystem, ensuring a skilled workforce capable of delivering high-quality diagnostic services. By combining cutting-edge technology, a comprehensive test menu, and a dedication to professional training, Dr Lal PathLabs plays a vital role in promoting health and well-being within the communities they serve.
Company Details
Key Leadership
Corporate Events
LALPATHLAB Share Price: Frequently Asked Questions
What is the current share price of Dr. Lal Path Labs Ltd.?
Dr. Lal Path Labs Ltd. (LALPATHLAB) trades at ₹1913.70 on NSE and BSE. Market cap ₹28.91K (Cr). Educational data only.
What is the P/E ratio of Dr. Lal Path Labs Ltd.?
Dr. Lal Path Labs Ltd. has a P/E of 53.35x vs industry average 42.23x.
What is the Bull Run score for Dr. Lal Path Labs Ltd.?
Dr. Lal Path Labs Ltd. has a Bull Run score of 57.7/100 based on 25+ financial parameters.
Does Dr. Lal Path Labs Ltd. pay dividends?
Dr. Lal Path Labs Ltd. has a dividend yield of 0.81%. Past dividends don't guarantee future payments.
What is the ROE of Dr. Lal Path Labs Ltd.?
Dr. Lal Path Labs Ltd. has ROE of 21.57%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Dr. Lal Path Labs Ltd.?
Dr. Lal Path Labs Ltd. has debt-to-equity of 0.00.
Is Dr. Lal Path Labs Ltd. a good investment?
Bull Run gives Dr. Lal Path Labs Ltd. a score of 57.7/100. This is not investment advice — consult a SEBI-registered advisor.